Advertisement
Logo
Search for

Volume 6, Issue 3, Pages 214-220 (September 2009)


View previous. 11 of 18 View next.

23Na MRI longitudinal follow-up of PDT in a xenograft model of human retinoblastoma

Mihaela Lupu, PhDabCorresponding Author Informationemail address, Carole D. Thomasab, Philippe Maillardbc, Bernard Loockbc, Benoit Chauvind, Isabelle Aertse, Alain Croisyab, Elodie Belloirab, Andreas Volkab, Joel Mispelterab

published online 20 November 2009.

Summary 

Background

Photodynamic therapy is an established cancer treatment in which a photosensitizing agent is activated by exposure to light thus generating cytotoxic reactive oxygen species that cause cellular damage.

Methods

A new photosensitizer synthesized at Curie Institute was used to treat retinoblastoma xenografts in mice, a glycoconjugated meso substituted porphyrin derivative, that showed some retinoblastoma cell affinity. The longitudinal follow-up of the tumors was carried out by 23Na MRI (without adding exogenous contrast agents) to map the extracellular compartment and to characterize cell packing. Two regimens were followed to target either blood vessels alone or blood vessels and cancer cells simultaneously.

Results and conclusions

Only the protocol targeting both cancer cells and blood vessels effectively induces cellular death, confirmed by histology at the end of the experiment. Sodium MRI evidences a huge change in the cellular density of tumors only 24h after a double targeting (vascular and cellular) PDT treatment. We suggest that this change was possibly due to a bystander effect that can be promoted by the intercellular signaling favored by the high cellular density of retinoblastoma. These results indicate that non-invasive 23Na imaging (which detects the tumor response to treatment from very early stages) in association with non-mutagenic therapies represents an effective option for tailored and individualized clinical treatments.

a U759 INSERM, Bât.112, Centre Universitaire, F 91405 Orsay cedex, France

b Institut Curie, Bât.112, Centre Universitaire, F 91405 Orsay cedex, France

c UMR 176 CNRS, Bât.112, Centre Universitaire, F 91405 Orsay cedex, France

d Univ. Paris-Sud, EA 4041, Laboratoire de Chimie Analytique, IFR 141, F92296 Chatenay Malabry, France

e Département d’Oncologie Pédiatrique, Institut Curie, F 75248, Paris cedex 05, France

Corresponding Author InformationCorresponding author at: Institut Curie, Bât.112, Centre Universitaire, F 91405 Orsay cedex, France. Tel.: +33 1 69 86 31 59; fax: +33 1 69 07 53 27.

PII: S1572-1000(09)00142-2

doi:10.1016/j.pdpdt.2009.10.009


View previous. 11 of 18 View next.

Advertisement